RxDoctor Payments Data

Mehwish Farooqi

Neurology · Sioux Falls, SDNPI 1982199303

Payments from drug & device makers

What this record shows

This record is dominated by grants: $10,000 of the $12,161 with a category attached, or 82.2%. Medtronic accounts for 95.7% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2022 at $11,609 and has fallen 96.9% since, to $355 in 2025.

$12,161in general payments, 2019–2025

Across 38 payments — averaging $320.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$12K
  • AbbVie$217
  • Amneal Pharmaceuticals LLC$111
  • Eisai Inc.$67
  • GE HealthCare$26
  • Abbott$25
  • plus $79 from 4 others

What the payments were for

  • Grants$10,00082%
  • Travel & lodging$1,45112%
  • Food & beverage$7106%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,161 in reported general payments places this provider in the 85th percentile of 49 neurology providers in South Dakota.

See all neurology providers in South Dakota

Medicare billing

Part B allowed, 2024
$59,498
Medicare patients
255
Services billed
691

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe35$36,199
Carbidopa-LevodopaCarbidopa/Levodopa584$18,506
RytaryCarbidopa/Levodopa12$16,330
NeuproRotigotine14$12,320
RivastigmineRivastigmine Tartrate47$4,072
Carbidopa-Levodopa ErCarbidopa/Levodopa60$3,041
Gabapentin98$1,735
Primidone92$1,625
Donepezil Hcl149$1,120
Pramipexole DihydrochloridePramipexole Di-Hcl31$688
Propranolol Hcl23$592
Ropinirole Hcl33$487
Topiramate36$355
AmantadineAmantadine Hcl15$349
Levetiracetam15$331

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary$111$16,33012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 49 neurology providers in South Dakota.

Other neurology in Sioux Falls

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →